Literature DB >> 22240425

Multidrug-resistant tuberculosis in Rawalpindi, Pakistan.

Muhammad Khurram1, Hamama Tul Bushra Khaar, Muhammad Fahim.   

Abstract

INTRODUCTION: Multidrug-resistant (MDR) tuberculosis (TB) strains are resistant to isoniazid and rifampicin. Clinical characteristics, drug susceptibility patterns, and outcomes of MDR-TB patients treated at Holy Family Hospital, Rawalpindi, Pakistan, were studied from January 2007 to April 2010.
METHODOLOGY: Thirty diagnosed patients (60% male and 40% female) of MDR pulmonary TB were included. Each patient was treated according to WHO guidelines and followed for two years. Clinical characteristics (age, gender, literate or illiterate educational status, employment status, and income), drug susceptibility testing (DST) reports, and outcome (cured, treatment failure, default, and died) of each patient was noted.
RESULTS: Mean patient age was 36.2 ± 15.4 years. In total, 60% patients were illiterate, 60% employed, 60% had income < Rs 5000 (42 Euro per month), 73.3% lived in an overcrowded residence, 60% were smokers, and 83.3% had taken anti-tuberculosis therapy previously. DST of MDR-TB strains for ethambutol, pyrazinamide, and streptomycin showed high resistance ( > 60%). Except for ofloxacin and ciprofloxacin, < 20% resistance was noted in second-line anti-tuberculosis agents. Overall, 10% of patients were cured, 40% died, 20% had treatment failure, and 30% patients defaulted.
CONCLUSION: Pulmonary MDR-TB in Rawalpindi, Pakistan, is common in young males, poverty related circumstances, and has poor outcome. DST shows high resistance to first- line anti-tuberculosis agents and quinolones.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22240425     DOI: 10.3855/jidc.1738

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  6 in total

1.  Trace elements in blood samples of smoker and nonsmoker active pulmonary tuberculosis patients from Jamshoro, Pakistan.

Authors:  Zainab Manzoor Memon; Erkan Yilmaz; Afsheen Mushtaque Shah; Ugur Sahin; Tasneem Gul Kazi; Bikha Ram Devrajani; Mustafa Soylak
Journal:  Environ Sci Pollut Res Int       Date:  2017-09-26       Impact factor: 4.223

2.  Strengthening the response to drug-resistant TB in Pakistan: a practice theory-informed approach.

Authors:  S Abbas; M Kermode; S Kane
Journal:  Public Health Action       Date:  2020-12-21

Review 3.  A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis.

Authors:  Michael G Whitfield; Heidi M Soeters; Robin M Warren; Talita York; Samantha L Sampson; Elizabeth M Streicher; Paul D van Helden; Annelies van Rie
Journal:  PLoS One       Date:  2015-07-28       Impact factor: 3.240

4.  Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients.

Authors:  Muhammad Atif; Arslan Bashir; Nafees Ahmad; Razia Kaneez Fatima; Sehar Saba; Shane Scahill
Journal:  BMC Infect Dis       Date:  2017-09-29       Impact factor: 3.090

5.  Understanding how geographic, demographic and treatment history impact health outcomes of patients with multi-drug-resistant tuberculosis in Pakistan, 2014-2017.

Authors:  F Iqbal; M K Defer; A Latif; H Hadi
Journal:  Epidemiol Infect       Date:  2020-09-30       Impact factor: 2.451

6.  Rifampicin resistance in Mycobacterium tuberculosis in Iran: a two-centre study.

Authors:  F Bahraminia; M Zangiabadian; M J Nasiri; M Fattahi; M Goudarzi; R Ranjbar; A A Imani Fooladi
Journal:  New Microbes New Infect       Date:  2021-06-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.